Report interim data for the PREVENT-19 Phase 3 trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 14 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Interim Data Expected Q2 '21”
What we found
Evidence strength A What the grades mean
Novavax reported primary efficacy data for the PREVENT-19 Phase 3 trial on June 14, 2021, which falls within the second quarter of 2021.
-
A Novavax Inc. 8-K filed 2021-08-06
“Reported final analysis from PREVENT-19 U.S. and Mexico Phase 3 trial oAchieved primary efficacy endpoint with overall efficacy of 90.4%” ✓ confirmed on the page
Market reaction: the shares moved -2.7% against the S&P 500 over the three sessions around the disclosure (5 Aug 2021 to 10 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- PREVENT-19 Phase 3 interim data
- Where
- United States and Mexico
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Novavax Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-NVAX-021475 · Corrections policy